ERAS (Erasca) ROCE % : -29.80% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Erasca ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Erasca's annualized ROCE % for the quarter that ended in Sep. 2024 was -29.80%.

Erasca ROCE % Historical Data

The historical data trend for Erasca's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Erasca ROCE % Chart

Erasca Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-25.20

-45.77

-32.93

-30.90

-33.88

Erasca Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-34.23	-35.57	-43.84	-43.09	-29.80

Erasca ROCE % Calculation

Erasca's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-141.525	/	( ( (514.909 - 48.69)	+	(395.297 - 26.156) )	/ 2 )
	=	-141.525	/	( (466.219	+	369.141)	/ 2 )
	=	-141.525	/	417.68
	=	-33.88 %

Erasca's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-148.968	/	( ( (525.744 - 24.893)	+	(528.896 - 30.025) )	/ 2 )
	=	-148.968	/	( ( 500.851	+	498.871 )	/ 2 )
	=	-148.968	/	499.861
	=	-29.80 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Erasca (NAS:ERAS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Erasca ROCE % Related Terms

Thank you for viewing the detailed overview of Erasca's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Erasca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121

Website

https://www.erasca.com

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Executives

Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: See Remarks	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding	director	C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Shannon Morris	officer: Chief Medical Officer	C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner	officer: General Counsel	C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Lim Conyee T.	10 percent owner	C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121